Englander Institute for Precision Medicine

Publications

Found 13 results
Author Title Type [ Year(Asc)]
Filters: Author is De Giorgi, Ugo  [Clear All Filters]
2023
Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, De Giorgi U et al..  2023.  Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.. J Urol. 209(3):532-539.
Fornarini G, Rebuzzi SE, Buti S, Rescigno P, Merseburger A, Sternberg CN, De Giorgi U, Basso U, Maruzzo M, Giannatempo P et al..  2023.  A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.. Minerva Urol Nephrol. 75(3):308-318.
2022
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J et al..  2022.  Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 18(35):3867-3874.
2021
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J et al..  2021.  Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.. Eur J Cancer. 159:237-246.
Oudard S, Benhamouda N, Escudier B, Ravel P, Tran T, Levionnois E, Negrier S, Barthelemy P, Berdah JFrançois, Gross-Goupil M et al..  2021.  Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.. Cells. 11(1)
Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U et al..  2021.  Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.. Oncologist. 26(12):1026-1034.
Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA et al..  2021.  Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.. J Clin Oncol. 39(14):1563-1574.
Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U et al..  2021.  Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.. J Clin Oncol. 39(14):1553-1562.
2020
Rescigno P, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin AG, Schmid S et al..  2020.  Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.. Eur Urol Oncol. 3(2):176-182.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP et al..  2020.  Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.. N Engl J Med. 382(23):2197-2206.
Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AShivaram, Powles T et al..  2020.  Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. Urol Oncol. 38(12):934.e1-934.e9.
2019
De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P et al..  2019.  Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.. Clin Cancer Res. 25(13):3839-3846.
Jayaram A, Wingate A, Wetterskog D, Conteduca V, Khalaf D, Sharabiani MTaghavi Az, Calabrò F, Barwell L, Feyerabend S, Grande E et al..  2019.  Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.. JCO Precis Oncol. 3